XERS — Xeris Biopharma Holdings Cashflow Statement
0.000.00%
Last trade - 00:00
- $259.44m
- $377.92m
- $163.91m
- 46
- 49
- 61
- 51
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -126 | -91.1 | -123 | -94.7 | -62.3 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 8.38 | 11.9 | 13.5 | 16.1 | 10.4 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 11.8 | -2.8 | 11.9 | -35.1 | -6.29 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -104 | -80.6 | -95.5 | -103 | -47 |
Capital Expenditures | -1.11 | -0.377 | -1.08 | -0.524 | -2.26 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -1.28 | -27 | 99 | 35 | -3.74 |
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -2.38 | -27.4 | 98 | 34.5 | -6 |
Financing Cash Flow Items | -6.85 | -10.3 | -0.054 | -4.88 | -1.19 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 80.5 | 126 | 27.2 | 127 | -1.61 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -26.2 | 18.1 | 29.7 | 59 | -54.6 |